Log in

NASDAQ:NYMXNymox Pharmaceutical Stock Price, Forecast & News

$3.66
+0.05 (+1.39 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.59
Now: $3.66
$3.75
50-Day Range
$3.01
MA: $3.64
$4.60
52-Week Range
$1.39
Now: $3.66
$4.79
Volume125,008 shs
Average Volume505,473 shs
Market Capitalization$260.67 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Read More
Nymox Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NYMX
CUSIPN/A
Phone800-936-9669

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120,000.00
Book Value$0.05 per share

Profitability

Net Income$-13,160,000.00
Net Margins-14,341.11%

Miscellaneous

EmployeesN/A
Market Cap$260.67 million
Next Earnings Date8/12/2020 (Estimated)
OptionableOptionable

Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter.

Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

How has Nymox Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Nymox Pharmaceutical's stock was trading at $2.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NYMX shares have increased by 59.8% and is now trading at $3.66. View which stocks have been most impacted by Coronavirus.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Nymox Pharmaceutical.

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Corp (NASDAQ:NYMX) posted its earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter. The biopharmaceutical company earned $0.01 million during the quarter. Nymox Pharmaceutical had a negative return on equity of 285.17% and a negative net margin of 14,341.11%. View Nymox Pharmaceutical's earnings history.

Has Nymox Pharmaceutical been receiving favorable news coverage?

Press coverage about NYMX stock has been trending negative on Monday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Nymox Pharmaceutical earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Nymox Pharmaceutical.

Who are some of Nymox Pharmaceutical's key competitors?

What other stocks do shareholders of Nymox Pharmaceutical own?

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the following people:
  • Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 68)
  • Mr. Erik Danielsen, Chief Financial Officer (Age 56)
  • Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 55)

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $3.66.

How big of a company is Nymox Pharmaceutical?

Nymox Pharmaceutical has a market capitalization of $260.67 million and generates $120,000.00 in revenue each year.

What is Nymox Pharmaceutical's official website?

The official website for Nymox Pharmaceutical is www.nymox.com.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.